Effects of two different oral anti diabetic drugs in type 2 diabetes mellitus patients

Objective: to examine and compare the effects of oral antidiabetic drugs in type 2 dm patients. design: prospective and comparative study. place and duration of study: study was conducted at the department of pharmacology,basic medical sciences institute (bmsi) in collaboration with medical department,jinnah postgraduate medical centre (jpmc) karachi,from january 2006 to july 2006. patients and methods: after scrutinized sixty newly untreated type 2 diabetes mellitus patients were enrolled in this study. females and males patients were divided in two groups. in group-i (n=27) patients were treated with drug pioglitazone 15mg after meal. in group-ii (n=33) patients were treated with drug glibenclamide 5mg early morning just before breakfast. patients with peptic ulcer,renal diseases,hepatic diseases,blood diseases,any serious complications were excluded from this study. general physical examination,pulse,blood pressure,routine investigation etc,was recorded at the time of patients enrollment and same assessments was taken at day 45 and at day 90. fasting and random blood sugar was calculated by glucose-oxidase enzymatic method. the data were expressed as the mean+sem at the end of study and was analysis by paired t test. results: out of seventy type 2 diabetes mellitus patients,60 patients were completed over all study period,tables shows the base line and post treatment values when results were summed up and the test parameters was compared,it was observed that drug glibenclamide decreasing blood sugar level in type 2 diabetes mellitus in a given time period. in parameter fbs mg/dl at day 45 mean values were 165.04 ± 8.98 p-value was p > 0.05 (non-significant),in parameter rbs mg/dl at day 45 mean values were 279.78±13.63 p-value was p>0.05 (non-significant),with pioglitazone group i patients. glibenclamide group ii patients,in parameter rbs (mg/dl) at day 45 mean values were 220.12±13.39 p-value from day 0 to day 45 was p < 0.005 (moderate significant),in the end of study period when results were compared visible differences was observed among in both groups . with glibenclamide group ii in parameter fbs mg/dl at day 90 mean values were 140.06 ± 5.68 p-value from day 0-90 was p<0.001 highly significant. conclusion: drug glibenclamide controlled type-2 diabetes mellitus by decreasing blood sugar level in a given study period as compared with other our study drug pioglitazone.